The proto-oncoprotein c-Myc and the multifunctional transcriptional regulator YY1 have been shown previously to interact directly in a manner that excludes Max from the complex (Shrivastava et al., 1993) . As binding to Max is necessary for all known c-Myc activities we have analysed the in¯uence of YY1 on cMyc function. We demonstrate that YY1 is a potent inhibitor of c-Myc transforming activity. The region in YY1 required for inhibition corresponds to a functional DNA-binding domain and is distinct from the domains necessary for direct binding to c-Myc. Furthermore the transactivation domain of YY1 was not necessary suggesting that gene regulation by YY1, for example through DNA bending or displacement of regulators from DNA, could be the cause for the negative regulation of c-Myc. This model of indirect regulation of c-Myc by YY1 was supported by the ®nding that although YY1 did not bind to the c-Myc transactivation domain (TAD) in vitro it was able to inhibit transactivation by Gal4-MycTAD fusion proteins in transient transfections. As for the inhibition of transformation, an intact DNA-binding domain of YY1 was necessary and sucient for this eect. In addition YY1 did not alter c-Myc/Max DNA binding, further supporting an indirect mode of action. Our ®ndings point to a role of YY1 as a negative regulator of cell growth with a possible involvement in tumor suppression.
Introduction
The proto-oncoprotein c-Myc is an essential transcription factor of the basic region (b), helix ± loop ± helix (HLH) and leucine zipper (Zip) class of transcriptional regulators (for review see Marcu et al., 1992; Henriksson and LuÈ scher, 1996) . Functionally c-Myc has been implicated in stimulating cell growth and inhibiting dierentiation and in speci®c cases in promoting apoptosis. As a consequence of deregulated and overexpressed c-Myc, tumor development and progression is facilitated (Henriksson and LuÈ scher, 1996) . Over recent years a number of c-Myc interacting proteins have been identi®ed some of which have been shown to modulate Myc function. Most notably the Cterminally localized HLHZip domain of c-Myc binds the nuclear protein Max, resulting in the formation of heterodimers which recognize palindromic DNA targets with the sequence CAC(G/A)TG, called Eboxes (Blackwell et al., 1993; Blackwood and Eisenman, 1991; Solomon et al., 1993) . Interaction with Max is essential for all Myc functions tested to date (Blackwood and Eisenman, 1991; Prendergast et al., 1991; Blackwood et al., 1992; Amati et al., 1993a,b) .
In addition to the bHLHZip domain, the transactivation domain (TAD) localized at the N-terminus of the protein is also essential for c-Myc function (Henriksson and LuÈ scher, 1996; Prendergast, 1997) . Regulation of the TAD may occur by several mechanisms including phosphorylation and interaction with dierent proteins. At least three phosphorylation sites have been mapped to the TAD (Henriksson et al., 1993; Gupta et al., 1993; Pulverer et al., 1994; Ham, 1994, 1997) . Two of these sites (Thr-58 and Ser-62 in human c-Myc) are in a region which is frequently mutated in c-myc genes of Burkitt lymphomas (Bhatia et al., 1993; Yano et al., 1993; Albert et al., 1994) . Consistent with the idea that these phosphorylation sites are of regulatory importance are the ®ndings that Thr-58 and/or Ser-62 Myc mutants display altered transforming ability (Henriksson et al., 1993; Pulverer et al., 1994) . The TAD has been implicated in the interaction of c-Myc with a number of proteins including the retinoblastoma related protein p107 and BIN1. Binding of p107 inhibits c-Mycspeci®c transactivation (Beijersbergen et al., 1994; Gu et al., 1994) . BIN1, a recently identi®ed novel protein, negatively regulates c-Myc-dependent transformation (Sakamuro et al., 1996) .
YY1 is a Zn-®nger transcription factor which is ubiquitously expressed and well conserved in evolution (Hariharan et al., 1991; Hahn, 1992; Shrivastava and Calame, 1994; Pisaneschi et al., 1994; Austen et al., 1997) . YY1 has been implicated in the regulation of a wide range of dierent promoters through various mechanisms. These include its function as an initiator binding protein Basu et al., 1993; Shenk, 1994, 1996) , a transactivator (Gaston and Fried, 1994; Bushmeyer et al., 1995; Furlong et al., 1996; Austen et al., 1997; Li et al., 1997a,b) as well as a repressor HannaRose and Hansen, 1996; Yang et al., 1996; Galvin and Shi, 1997) . Furthermore repression by inhibiting activators through DNA bending, displacement from DNA or direct protein ± protein interaction (Natesan and Gilman, 1993; Meier and Groner, 1994; Lu et al., 1994; Zhou and Engel, 1995; Guo et al., 1997) or by modulating DNA-binding activity of other factors (Natesan and Gilman, 1995) have been described. In addition YY1 has been found as part of an RNA polII holoenzyme (Maldonado et al., 1996) . Repressing as well as activating functions of YY1 have been reported to be regulated by the viral oncoprotein E1A, presumably mediated by proteins of the p300/CBP family of coactivators Lee et al., 1995; Furlong et al., 1996; Galvin and Shi, 1997) . E1A interacts with and modulates a number of cellular proteins, e.g. p105RB and related pocket proteins, cyclin A and the p300/CBP-family of proteins, all of which are thought to be regulators of cell growth (Whyte et al., 1989; Shenk and Flint, 1991; Arany et al., 1995) , suggesting that YY1 may also be involved in the control of cellular proliferation.
c-Myc has been identi®ed as an interaction partner for YY1 in a yeast two-hybrid screen (Shrivastava et al., 1993) . Direct binding between both proteins has been reported in vitro as well as in vivo (Shrivastava et al., 1993 (Shrivastava et al., , 1996 . The interaction domain in c-Myc has been mapped to the C-terminal half including the bHLHZip domain. No evidence for a ternary complex of c-Myc, Max and YY1 could be obtained suggesting that c-Myc cannot bind to Max and YY1 at the same time (Shrivastava et al., 1993) . In transient assays, cMyc was capable of inhibiting both the activation and repression functions of YY1 (Shrivastava et al., 1993) .
Given the exclusive nature of binding of Max and YY1 to the C-terminus of c-Myc and the dependence of c-Myc on binding to Max to be functional we asked whether YY1 could act as a negative regulator of cMyc via competition with Max. In this paper we present data showing that YY1 is indeed a negative regulator of c-Myc. However, this eect is independent of direct binding to c-Myc but rather targets the c-Myc TAD. This occurs through an indirect mechanism requiring the DNA-binding function of YY1. Thus YY1 appears to regulate upstream modulators of cMyc.
Results

YY1 is a potent inhibitor of c-Myc/Ha-Ras co-transformation
To analyse the role of YY1 in the regulation of c-Myc we tested whether YY1 could alter the transforming activity of c-Myc. YY1 was able to strongly inhibit the co-transformation of rat embryo cells (RECs) by cMyc and Ha-Ras (Figure 1a) . In order to identify the domains required in YY1 for inhibition of transformation, we tested a panel of YY1 deletion mutants (Figure 1b) (Austen et al., 1997) . Deletion of the Nterminal half of the protein, including the bipartite TAD and the Gly/Ala-rich region, did not alter the ability of YY1 to interfere with c-Myc/Ha-Ras transformation (see Figure 1c for a schematic map showing major features of YY1). However, deletions aecting the Zn-®nger domain resulted in proteins which were either less potent or unable to inhibit transformation (YY1D262 ± 299, YY1D296 ± 331, YY1D334 ± 414, and YY1D399 ± 414). In these mutants, the ®rst, the ®rst and the second, the second to fourth, and the fourth zinc ®ngers were disrupted, respectively. In every case these mutations resulted in loss of both DNA binding and transactivation activity (Austen et al., 1997) which is consistent with the ®nding that all four zinc ®ngers make DNA contacts (Houbaviy et al., 1996) . Deletions outside of the DNAbinding domain which generate proteins still able to bind DNA do not signi®cantly alter the eect on Myc/ Ras transformation although some of the mutant proteins, due to the deletion of the TAD, cannot transactivate (Bushmeyer et al., 1996 , Austen et al., 1997 . These ®ndings suggested that for the inhibition of c-Myc/Ha-Ras transformation by YY1 a functional DNA binding domain is necessary and sucient. Deletion mutants D2 ± 150 and D2 ± 273 are expressed at lower levels than wild type (Austen et al., 1997) which can account for their slightly reduced activity in (Austen et al., 1997) were tested for their in¯uence on Myc/Ras co-transformation of RECs. The number of foci obtained with Myc and Ras alone was set as 100%. (c) Graphical representation of YY1 primary structure. Acidic regions 1 and 2: bipartite transactivation domain; His-cluster: a stretch of 11 consecutive His residues; GA-rich: Gly-and Ala-rich region; spacer: region with no recognized structural elements, is required for optimal transactivation; Zn-®nger: DNA-binding domain of four Zn-®ngers. The part of YY1 needed for ecient inhibition of transformation is indicated suppression of transformation. All other mutant proteins are expressed at levels similar to wild type YY1 (Austen et al., 1997) , excluding the possibility that the inability of some of the mutants to repress transformation is due to inecient expression.
c-Myc and Ha-Ras levels as well as Ras function are not aected by YY1 YY1 has been described to regulate a number of diverse promoters positively as well as negatively. It was therefore possible that the observed reduction in transformation eciency was a result of a reduced expression of c-Myc and/or Ha-Ras. After transfection of the corresponding vectors into RECs in the presence or absence of a YY1 expression plasmid, no dierence in the levels of either c-Myc or Ha-Ras could be detected by Western blotting (Figure 2a ). This demonstrated that the YY1-mediated inhibition of transformation is not simply the result of decreased Myc or Ha-Ras levels.
In order to test whether YY1 negatively regulated the function of Ha-Ras, we analysed the in¯uence of YY1 on the activation of Elk-1 mediated transcription by Ha-Ras. The Elk-1 protein is a member of the Etsfamily of transcription factors and represents a well characterized target of the Ras/MAP-kinase signal transduction cascade (Janknecht et al., 1993) . We could not detect a signi®cant in¯uence of YY1 on the stimulation of a reporter plasmid containing E74-Etsbinding sites in front of the HSV tk-promoter by HaRas and Elk-1 (Figure 2b ). This supported the concept that the inhibition of Myc/Ha-Ras co-transformation by YY1 was the result of a decrease in the transforming activity of c-Myc.
The transcription factor E2F is a key regulator of cellular progression through the cell cycle (Nevins, 1992; Weinberg, 1995) . We therefore asked whether E2F-activity was in¯uenced by YY1. As an assay system we chose the B-myb-promoter which contains E2F-sites as major determinants of activity (Lam et al., 1994) . As shown in Figure 2c , ectopic YY1 had no eect on the activity of this promoter in RECs, demonstrating that the inhibition of Myc/Ha-Ras cotransformation by YY1 is not due to an inhibition of E2F-mediated transcription.
The Gly/Ala-rich region and a central part of the YY1 DNA-binding domain are necessary for interaction with c-Myc A large C-terminal domain of YY1 (amino acids 201 ± 343) was originally described as important for binding to c-Myc (Shrivastava et al., 1993 (Shrivastava et al., , 1996 . Since some of our mutants were still able to inhibit c-Myc/Ha-Ras transformation although part of the previously de®ned interaction domain was deleted (YY1D199 ± 273, D2 ± 273) we mapped the interaction domain in YY1 required to bind to c-Myc in vitro in more detail. YY1 and the dierent deletion mutants were overexpressed in COS7 cells and then assayed for their ability to bind to glutathion-S-transferase (GST)-Myc(262 ± 431) or to GST-Myc(1 ± 262) fusion proteins. Wild type YY1 and several of the mutants were able to bind to the C-terminal fragment of c-Myc (Figure 3a) , whereas no binding to the N-terminal TAD of c-Myc could be observed (Figure 3b ). Mutants with deletions of the Gly/Ala-rich region or with deletions of the central region of the Zn-®nger domain (amino acids 299 ± 399) were no longer able to bind to the C-terminus of c-Myc. Thus two separate domains are required for ecient binding of YY1 to c-Myc which are distinct from the regions required for inhibition of transformation ( Figure 3c ).
Myc/Max complexes are not disrupted by YY1
The ®ndings described above revealed that the domains required for inhibition of c-Myc/Ha-Ras transforma- (a) Rat embryo cells were transfected with empty expression vectors or with pSP-c-Myc, pVEJB-Ha-Ras or pSP-YY1 using the same conditions and amounts as for transformation assays. After 36 h, whole cell extracts were prepared and expression of c-Myc, Ras and YY1 analysed by Western blotting, using a-Myc 6A10, a-Ras p21 and a-YY1 263. (b) RECs were transiently transfected with the reporter plasmid E74 3 -TK-luc containing three E74 Etsbinding sites in front of the HSV TK-promoter (7105 to +53, Janknecht et al., 1993) and 50 ng pRSV-Elk-1, 2 mg pVEJB-HaRas and 1 mg pCMV-YY1 as indicated. Luciferase activity was determined after 36 h. (c) A reporter plasmid containing the human B-myb-promoter up to position 7536 in front of a luciferase gene (Lam et al., 1994) was transiently transfected into RECs with or without 1 mg pCMV-YY1 and luciferace activity was determined 36 h after transfection (the error bar was too small for the +YY1 samples)
Inhibition of c-Myc by YY1 M Austen et al tion and interaction with c-Myc were only partially overlapping. Importantly, some mutants were unable to bind to c-Myc in vitro, yet inhibited transformation (D154 ± 199, D2 ± 273). Others still bound to the Mycfusion protein but did not inhibit transformation eciently (D262 ± 299, D399 ± 414). This suggested that the repression of c-Myc/Ha-Ras transformation by YY1 was not due to a direct interaction of these two proteins. To test more directly whether the physical interaction of YY1 with c-Myc could be relevant for cMyc function, we examined whether YY1 aects cMyc/Max DNA-binding. Two dierent outcomes could be envisioned. First binding of YY1 to c-Myc could displace Max and by this inhibit c-Myc/Max DNA binding and second YY1 may interact with the c-Myc/Max heterodimer resulting in a trimeric complex with altered mobility in an electrophoretic mobility shift assay (EMSA). Therefore, c-Myc and Max were overexpressed in COS-7 cells either in the absence or in the presence of increasing amounts of YY1 expression plasmids. Whole cell extracts were prepared and the eect of YY1 on the DNA-binding activity of c-Myc/ Max complexes determined. In c-Myc and Max containing extracts distinct Max/Max and c-Myc/Max complexes were detected using EMSA (Figure 4a ). Coexpression of YY1 did neither inhibit nor alter the mobility of c-Myc/Max complexes. Similarly the addition of bacterially expressed and puri®ed YY1 (Austen et al., 1997) did not eect c-Myc/Max DNA binding (data not shown). As shown above for RECs (Figure 2a ), YY1 did not alter the expression of c-Myc or Max in COS7 cells although YY1 levels were substantially increased (Figure 4b) . Thus under the conditions used YY1 is unable to interfere with c-Myc/ Max DNA-binding and hence to compete with Max binding to c-Myc. Together the ®ndings described above suggest that YY1 aects c-Myc function by a mechanism distinct from direct binding.
YY1 negatively regulates the Myc transactivation domain
As a next step we examined whether YY1 could modulate the activity of the c-Myc TAD. The in¯uence of YY1 and YY1 mutants on the ability of a fusion Aliquots from the same extracts used in a were separated by SDS ± PAGE and protein expression analysed by Western blotting using mAb 6A10 for c-Myc, polyclonal antibodies 263 for YY1 and C-17 for Max (Figure 5a ). Identical observations were made by performing corresponding experiments in established cell lines (data not shown). The repressive eect of YY1 on the c-Myc transactivation domain was speci®c since a number of other promoters (SV40-, Ha-ras-, E74 3 -tk-, B-myb-, and CMV-promoter) were not aected (Figures 2 and 4) . Furthermore the transactivation domains of c-Myb, c-Fos, NF-M, and USF when fused to the Gal4 DNA-binding domain were not repressed by YY1 (Figure 5b) . Thus YY1 mutants which inhibited transactivation by interfering with the TAD of c-Myc also inhibited c-Myc/Ha-Ras co-transformation whereas mutants which did not aect transformation stimulated transactivation. Together these ®ndings indicate that YY1 modulates cMyc activity at least in part by interfering with its TAD.
DNA-binding of YY1 is necessary for inhibition of c-Myc
As shown in Figure 3b , there is no direct interaction between the transactivation domain of c-Myc and YY1. The inhibition by YY1 could therefore be mediated by the product of a gene whose transcription is regulated by YY1 or through the binding of YY1 to a factor which is necessary for the ecient functioning of the c-Myc TAD. The DNA-binding domain of YY1 is most likely sucient for the regulation of a certain subset of YY1-modulated genes, for example in situations where YY1 exerts its eect by displacement of other regulatory factors from DNA (Meier and Groner, 1994; Lu et al., 1994; Guo et al., 1997) or through DNA bending (Natesan and Gilman, 1993) . In order to distinguish between the two mechanisms, we constructed a new YY1 mutant with Lys-339 and Arg-342 in the second zinc ®nger domain mutated to serine residues (YY1S339/S342). Lys-339 and Arg-342 have been shown to make important contacts with the two Gs in the ATGG-core of the YY1 recognition sequence as well as with the DNA backbone (Houbaviy et al., 1996) . Figure 6a shows that the resulting protein no longer bound to DNA when used in a band-shift experiment with a binding site from the immunoglobulin kE3' enhancer (Park and Atchison, 1991) . Identical results were obtained with a binding site from the Adeno Associated Virus P5-promoter (P5+1, Shi et al., 1991, data not shown). In addition YY1S339/S342 was expressed to similar levels as the wild type protein and localized to the nucleus ( Figure  6b and data not shown). In a GST-pull-down assay it bound with equal anity as the wild type protein to GST-Myc(262 ± 439) ( Figure 6c ) as well as to a number of other known interaction partners (TFIIB, the TATA-binding protein TBP, CBP/p300; Austen et al., 1997; data not shown), indicating that the amino acid changes did not result in a major conformational alteration of the DNA-binding domain. However, the mutant protein was unable to inhibit the c-Myctransactivation domain (Figure 6d ). YY1S339/S342 was also unable to block Myc/Ha-Ras co-transformation ( Figure 6e ). These results again reinforce our ®ndings that direct binding of YY1 to Myc is not involved in the inhibition of Myc/Ha-Ras transformation. In addition they show that DNA binding is necessary for the inhibitory function of YY1, a ®nding that is consistent with the negative regulation of c-Myc through a YY1-regulated gene product. Formally it cannot be excluded that the two mutations disturb the binding of YY1 to an unknown co-activator protein of c-Myc. However, this seems unlikely as binding to several YY1-interaction partners is unaected although the point mutations lie within a domain of YY1 which is necessary for binding to these proteins (Austen et al., 1997) . Also, since Lys-339 and Arg-342 face towards the DNA in the DNA-bound state of the protein, they are less likely to be part of a protein ± protein interaction interface.
Discussion
We have addressed a possible role of the transcription factor YY1 as a negative regulator of the c-Myc protooncoprotein. Such a connection had been suggested by earlier ®ndings showing that c-Myc can interact directly with YY1 in a manner that prevents the interaction between c-Myc and Max (Shrivastava et al., 1993; and that c-Myc/Max complex formation is essential for c-Myc function (Amati et al., 1993a,b) Our data demonstrate that YY1 can act as a potent negative regulator of c-Myc/Ha-Ras co-transformation of RECs (Figures 1 and 6 ). Unexpectedly a direct interaction between YY1 and c-Myc is not needed for inhibition of transformation. A detailed analysis of the regions in YY1 required for the inhibitory eect revealed that an intact DNA-binding domain of YY1 is necessary and sucient ( Figures 1, 4 ± 6 ). In addition our ®ndings show that Ras is not aected by YY1 (Figure 2 ). Our data suggest that the c-Myc TAD is the target of YY1 action. The ®rst indication that the interaction between cMyc and YY1 may not be important for inhibition of c-Myc function came from transformation studies. We noticed that the region in YY1 necessary for inhibition of transformation did not coincide with the published c-Myc interaction domain (amino acids 201 ± 334 in YY1, Shrivastava et al., 1993 Shrivastava et al., , 1996 . Therefore we have performed a detailed in vitro mapping to identify the region in YY1 relevant for binding to Myc ( Figure  3) . We found that two domains in YY1 are necessary for an ecient interaction with a GST-c-Myc fusion protein, the Gly/Ala-rich region (amino acids 154 ± 199) and the core of the DNA-binding domain (amino acids 299 ± 399). We have currently no explanation for the dierence between the regions mapped as important by us and by Shrivastava et al. (1993 Shrivastava et al. ( , 1996 . However, the domain in YY1 important for inhibition of transformation coincides with neither region. We therefore concluded that YY1 inhibits cMyc function via a mechanism independent of direct binding. This is consistent with our ®ndings that even strong overexpression of YY1 does not lead to a displacement of Max and subsequent disruption of DNA-binding by Myc/Max complexes. However, in situations where cellular c-Myc concentrations are highly elevated as for example in Burkitt Lymphoma cells a modulation of YY1 activity via direct interaction with c-Myc may still be relevant (Shrivastava et al., 1993 (Shrivastava et al., , 1996 .
In search for alternative explanations for the YY1 eect we performed transfection experiments using fusions between the Gal4 DNA-binding domain and the c-Myc TAD. We could demonstrate an inhibition of Gal4-Myc(1 ± 262)-mediated transactivation by YY1 which was dependent on the same part of the protein that was also needed for the inhibition of transformation (Figures 1, 5 and 6 ). The TADs of the transcriptional activators NF-M, USF, and c-Myb were either not or only poorly inhibited by YY1 whereas the c-Fos TAD was stimulated, demonstrating that the inhibition of the c-Myc TAD is not an unspeci®c eect (Figure 5b ). Since YY1 did not interact with the Myc TAD, the eect on this domain appears to be indirect. For both, inhibition of transformation and transactivation, the DNA-binding domain of YY1 is sucient (Figures 1, 5 and 6 ). How can the YY1 DNA-binding domain in the absence of a TAD aect gene transcription? Several mechanisms for YY1 action have been proposed which may depend only on a functional DNA-binding domain. It could be sucient for the initiator function of YY1 Shenk, 1994, 1996) or for regulating genes simply through binding to target sequences, either by displacing other regulators or through DNA bending (Natesan and Gilman, 1993; Lu et al., 1994; Meier and Groner, 1994; Zhou and Engel, 1995; Guo et al., 1997) . Thus we postulate that the product(s) of one or several genes regulated by YY1 through one of these mechanisms modulate(s) the activity of the c-Myc transactivation domain (Figure 7 ). Another possibility would be the sequestration of a factor necessary for c-Myc transactivation through direct binding by the DNA-binding domain of YY1. We have tried to distinguish between mechanisms involving DNA binding or protein ± protein interactions with the help of a mutated YY1 carrying point mutations in the Zn-®nger domain (YY1S339/S342) which abolished DNA binding. While this protein still bound to TFIIB, TBP, p300/CBP (Austen et al., 1997;  data not shown) and most importantly to c-Myc (Figure 6 ), it failed to inhibit c-Myc/Ha-Ras transformation and transactivation by the c-Myc TAD (Figure 6 ). c-Myc has been shown to interact with TBP (Hateboer et al., 1993; Maheswaran et al., 1994) , thus the binding of YY1 to TBP may aect TBP-c-Myc interaction and thereby modulate c-Myc function. However it is unlikely that YY1 aects cMyc through TBP since YY1S339/S342 still bound to TBP but did no longer inhibit Myc-speci®c transformation and transactivation. Also we could not detect an eect of p300/CBP on c-Myc transactivation in transient transfections (MA, unpublished observation) . Together with the ®nding that YY1S339/S342 still binds p300/CBP, these proteins are most likely not relevant for the inhibition of c-Myc by YY1. Recently it was reported that YY1 interacts with histone deacetylases (HDACs) (Yang et al., 1996 . HDACs have also been implicated in mediating functions of the Myc/Max/Mad network (Alland et al., 1997; Hassig et al., 1997; Heinzel et al., 1997; Laherty et al., 1997; Sommer et al., 1997) . Again binding of YY1 to HDACs does not seem to be relevant since the Gly/Ala-rich domain (aa 154 ± 199) in YY1, which mediates interaction with HDACs, can be deleted without eect (Figures 1 and 5) . These ®ndings support the idea that the inhibition of c-Myc function by YY1 is independent of direct interaction with the known YY1 binding partners and with c-Myc itself and demonstrate that DNA binding of YY1 and most likely the regulation of a Myc-modulating gene is the basis for the observed eects (Figure 7 ). At present we do not know which YY1-regulated genes are relevant for the inhibition of the c-Myc transactivation domain. Preliminary ®ndings indicate that neither p107 nor BIN1 (Beijersbergen et al., 1994; Gu et al., 1994; Sakamuro et al., 1996) negatively regulate Gal4-Myc(1 ± 262) in RECs and that they do not modulate the YY1-dependent inhibition (MA, unpublished observation). Thus it is unlikely that p107 and BIN1 are the YY1 targets responsible for aecting Myc function.
In order to de®ne regions in the c-Myc TAD targeted by YY1 we have used Gal4-Myc-fusions containing deletions either in Myc box I or II or which had point mutations (Thr-58, Ser-62) in phosphorylation sites which have been implicated in transformation (Desbarats et al., 1996; Henriksson et al., 1993) . All proteins activated transcription strongly in our system and were inhibited by YY1 to a similar extent (MA, unpublished observation). The failure to identify a small domain in the c-Myc TAD could have several reasons. One possibility is that the mutants were not assayed in the background of c-Myc but rather in a fusion protein which may aect the sensitivity to the YY1 regulated mechanism. Differences between the structural requirements in transient transfections comparing c-Myc with Gal4-MycTAD fusions as well as between transient transfections and transformation and S phase progression assays have been noted (Desbarats et al., 1996; Sakamuro et al., 1996) . In addition we have analysed the in¯uence of YY1 on the ODC-promoter (Bello-Fernandez et al., 1993) . The activation by c-Myc obtained in our hands with corresponding reporter constructs was in the range of 1.5 ± 2-fold under a range of conditions (including constitutive or inducible Myc constructs; exponentially growing, serum-starved or contactinhibited cells; in the presence or absence of activated Ras). This small activation was blocked by YY1 but did not allow us to faithfully assay c-Myc-or YY1 mutants (data not shown). However, this ®nding suggested that transactivation of a natural target gene of c-Myc is also YY1 sensitive. Another possibility is that YY1 targets more than one region within the cMyc TAD which will require further analysis.
c-Myc is a powerful regulator of cellular growth, dierentiation, transformation and apoptosis (for review see Marcu et al., 1992; Packham and Cleveland, 1995; Henriksson and LuÈ scher, 1996) . Therefore its activity must be tightly controlled and balanced by a number of dierent mechanisms. Our ®ndings suggest that YY1 represents such a regulator. At present little is known about how the activity or the expression of YY1 are regulated and thus little information is available about the regulation of the interplay between YY1 and c-Myc. One possibility is that YY1 may establish a threshold which must be overcome by c-Myc in order to stimulate cell growth. This would be consistent with the notion that YY1 is ubiquitously and constitutively expressed at relatively high levels under most conditions studied (Hariharan et al., 1991; Hahn, 1992; Shrivastava and Calame, 1994; Pisaneschi et al., 1994; Austen et al., 1997) . Such a mechanism could be operating during the G0 to G1 transition or upon induction of dierentiation when the levels of c-Myc are modulated and the ratio between c-Myc and YY1 is changed.
However it is also possible that YY1 functions are not exerted constitutively. Despite its abundance, constitutive expression and involvement in RNA polII holoenzyme complexes (Maldonado et al., 1996) , YY1 may be involved in the regulation of speci®c cell cycle events. Other factors which are constitutively expressed such as certain TBP-associated factors have been shown to aect transcription of certain genes at speci®c times in the cell cycle (Moqtaderi et al., 1996; Shen and Green, 1997; Walker et al., 1997; Wang et al., 1997) . Alternatively YY1 may be a component of an upstream signaling pathway which targets c-Myc and aects its function. Since YY1 is a phosphoprotein, regulation of its phosphorylation status could contribute to changes in YY1 activity (Becker et al., 1994; Austen et al., 1997) .
A role for YY1 as negative regulator of cell growth is also supported by the ®ndings that YY1 is targeted by the viral oncoprotein E1A Lee et al., 1995) . Furthermore recent results indicate that YY1 may be part of a cellular stress response pathway activated by misfolded proteins (Li et al., 1997a,b) . Thus it is possible that eects on cell growth by certain forms of stress could be mediated by YY1-dependent negative regulation of cell growth. Whether all these eects are the result of negatively regulating c-Myc function is unclear and has to be addressed in future studies. Our results indicate that YY1 may have tumorsuppressing properties. While the ubiquitous expression and the strong conservation of YY1 in evolution suggests an essential role of YY1 in the cell, mutation of a single allele might be sucient to confer a growth advantage. It will now be important to identify a gene(s) which is regulated by YY1 and whose protein product(s) aects c-Myc function.
Materials and methods
Plasmids and in vitro mutagenesis
The SV40 based expression plasmid pSP-myc and the HaRas-expression vector pVEJB-Ha-ras have been described previously (Cerni et al., 1995) . Constructs containing dierent YY1 mutants in pSP were generated by cutting out coding regions from the pCMV-YY1 series (Austen et al., 1997) with EcoRI and insertion into the EcoRI site of pSP. The mutant YY1S339/S342 was generated by PCR using primers containing corresponding base changes which overlapped the HindIII and FspI sites in the YY1 cDNA. The reaction product was cut with both enzymes and the resulting fragment inserted into pBS-YY1 cleaved with HindIII and partially with FspI (Austen et al., 1997) . PCR-derived sequences were veri®ed by sequencing. The mutant sequence was then recloned into pSP and pCB6+ to give pSP-YY1S339/S342 and pCMV-YY1S339/S342, respectively. Expression vector pRSV-elk-1 and the reporter pE74 3 -tk80-luc were a gift of R Janknecht (Janknecht et al., 1993) . The E74 site is a natural binding site for the Drosophila Ets protein E74. Elk-1 also binds to the E74 site directly with high anity and without any requirement for SRF (Janknecht and Nordheim, 1992) . The B-myb reporter construct pGL(-536)-B-myb was provided by R Watson (Lam et al., 1994) , the plasmid expressing Gal4-MycTAD was from C Dang (Kato et al., 1990) , Gal4-NF-M from A Leutz (Kowenz-Leutz et al., 1994) , Gal4-USF from M Eilers (Desbarats et al., 1996) , Gal4-Myb from K Moelling (Kalkbrenner et al., 1990) , and Gal4-Fos from T Kouzarides (Bannister and Kouzarides, 1995) . pGEXmyc(1 ± 262) and pGEXmyc(262 ± 439) were obtained from B Blackwood and R Eisenman.
Cell culture
Rat embryo cells (RECs) were prepared from 15.5 day old Fischer rat embryos as described (Cerni et al., 1989) and stored in liquid Nitrogen until use. For transfections or transformation assays, aliquots were thawed, passaged once and then seeded as indicated. Cells were kept in Dulbecco's modi®ed Eagle medium supplemented with 10% fetal calf serum and 1% penicillin/streptomycin.
Transient transfection
Rat embryo cells were transiently transfected using the calcium phosphate method as described (Chen and Okayama, 1988; Bousset et al., 1994) . Brie¯y, cells were plated at a density of 1.5610 5 cells/plate. Each 6 cm plate received 2 mg of reporter plasmid, 1 mg pRSVlacZ as internal control, and the amounts of eector plasmids indicated. The amount of expression vector was kept constant with the corresponding empty vector and total DNA brought to 10 mg per plate with pBluescript (Stratagene). All transfections were done in duplicates and all experiments were performed at least three times, means and standard deviations are indicated. Cells were harvested after 36 ± 48 h and luciferase and b-galactosidase activities were determined (Bousset et al., 1994) .
Transformation assays
Rat embryo cells (RECs) were plated at a density of 5610 6 cells per 10 cm dish and transfected the next day with 5 mg pSP-myc, 5 mg pVEJB-Ha-ras and 10 mg pSP or the indicated pSP-YY1 constructs. Cells were split the day after transfection and replated on four or ®ve 6 cm dishes. Staining with Giemsa and counting of foci was done 10 ± 14 days later as described previously (Cerni et al., 1995) .
GST-pull-down assays COS7 cells were transiently transfected with CMVpromoter-based expression constructs for the dierent YY1 mutants (Austen et al., 1997) and harvested in 300 ml/10 cm plate of F-buer (10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 5 mM ZnCl 2 , 100 mM Na 3 VO 4 , 1% Nonidet P-40 (NP-40), 1 mM phenylmethylsulfonyl¯uoride (PMSF), 5 U a 2 -macroglobulin per ml, 2.5 U of pepstatin per ml, 2.5 U of leupeptin per ml, 0.15 mM benzamidine, 2.8 mg of aprotinin per ml), vortexed for 45 s and subsequently centrifuged at 48C and 14 000 r.p.m. for 15 min (OelgeschlaÈ ger et al., 1995). GST-fusion proteins were overexpressed in BL21 bacteria and puri®ed with glutathioneagarose. 10 mg of the indicated GST-fusion protein was bound to 15 ml glutathione-agarose and incubated with 50 ml COS7-lysate in 250 ml binding buer (20 mM HEPES, pH 7.5, 100 mM NaCl, 2.5 mM MgCl 2 , 0.1 mM EDTA, 0.05% Triton X-100, 10 mM DTT) (OelgeschlaÈ ger et al., 1996) at 48C for 90 min with rocking. Beads were then washed three times with binding buer and bound proteins were analysed by sodium dodecyl sulfate polyacrylamide electrophoresis (SDS ± PAGE) and Western blotting.
Western blotting and antibodies
For Western blotting, cells were transfected as for reporter gene assays. Cells were then lysed in antibody buer (20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.5% deoxycholate, 0.5% SDS, 0.5% aprotinin) (LuÈ scher and Eisenmann, 1988) , standardized for b-galactosidase activity, and separated by SDS ± PAGE. Staining was carried out using the enhanced chemoluminescence system (Amersham) according to the instructions of the manufacturer or with an alkaline phosphatasecoupled secondary antibody and nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate as chromogenic substrate. YY1 was detected either with a-YY1 C20 (Santa Cruz) or with a-YY1 263 (Austen et al., 1997) as indicated. a-Ras p21 was purchased from Transduction Laboratories, a-c-Jun (N) and a-Max (C17) from Santa Cruz. The Mad1 speci®c mAb 5F4 has been described previously (Sommer et al., 1997) . Preparation and characterization of the monoclonal a-c-Myc antibody 6A10 is described elsewhere (Sommer et al., 1998) .
Electrophoretic mobility shift assay
For EMSA, COS7 cells were transfected with the indicated constructs and harvested in F-buer as for GST-pull down assays. Oligonucleotides were end-labeled with g-32 P-ATP followed by ®ll-in of overhangs with the Klenow fragment of E. coli PolI (OelgeschlaÈ ger et al., 1995) . YY1 binding sites were the P5+1-site from Adeno Associated Virus (5'-GATCAGGGTCTCCATTTTGAAGCGGGATC-3'; or a site from the immunoglobulin k3'-enhancer (5'-GATCCTACCCCACCTCCATCTTGTTTGAAGATC-3'; Park and Atchinson, 1991). 1 ml of cell extract was incubated with 0.1 ± 0.5 ng of probe in 12 mM HEPES, pH 7.9, 10% glycerol, 5 mM MgCl 2 , 60 mM KCl, 1 mM bmercaptoethanol, 50 mg/ml bovine serum albumine, 0.05% NP-40 at 308C for 30 min. The DNA-protein complexes were separated on 5% polyacrylamide gels in TBE (25 mM Tris base, 25 mM boric acid, 0.5 mM EDTA) at 48C and 20 V/cm. For Myc/Max band shifts, the binding site used was 5'-TCAGACCACGTGGTCGGG-3' (CMD; Prendergast et al., 1991; Bousset et al., 1994) . The conditions are described in detail elsewhere (Sommer et al., 1998) .
